Scientists have discovered a marker in the blood that could predict the risk of developing kidney cancer.
News
ViiV, Janssen’s two-drug HIV regimen hits PhIII targets
ViiV Healthcare and Janssen have unveiled positive headline data from a late-stage trial of their injectable two-drug regimen for the treatment of HIV.
All London GP practices now using electronic prescriptions
GP practices across London have successfully made the switch to using the Electronic Prescription Service (EPS), saving hours of time and money, NHS Digital says.
Emergency hospital visits more likely for deprived bowel cancer patients
Emergency hospital visits are more common among patients with bowel cancer living in the most deprived areas of the country than for those living in affluent regions, research funded by Cancer Research UK has found.
Four new medicines cleared for use on NHS Scotland
The Scottish Medicines Consortium has approved funding for four newly licensed medicines, expanding NHS treatments options in Scotland for ovarian cancer, lung cancer, urea cycle disorders and acute hereditary angioedema.
Xolair deemed ‘breakthrough’ therapy for food allergies
Roche/Novartis’ Xolair has been awarded breakthrough status in the US for treatment of severe allergic reactions after accidental exposure to foods allergens.
Draft guidelines reject NHS funding for Biogen’s Spinraza
The National Institute for Health and Care Excellence is not recommending NHS use of Biogen’s Spinraza for the rare genetic disorder spinal muscular atrophy (SMA) at this time.
Motif Bio’s antibiotic granted US priority review
US regulators have accepted for review a targeted, Gram-positive investigational antibiotic developed by UK biopharma Motif Bio for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
Orchard raises $150m to advance gene therapies
UK-American biotech Orchard Therapeutics has raised $150 million to fuel development of its gene therapy pipeline.
Bowel cancer screening to start 10 years earlier
Bowel cancer screening in England and Wales is to start a decade earlier in a drive to pick up more cases of the disease at an earlier stage, the government has confirmed.
Amicus’ Galafold wins US approval
Amicus Therapeutics’ Galafold has been approved in the US as the first oral medication for the treatment of adults with Fabry disease.
Astellas buys UK group Quethera
Astellas has acquired Cambridge, UK-based Quethera, a gene therapy group focused on the development of novel treatments for ocular disorders, such as glaucoma.
Alnylam’s novel RNA therapy Onpattro wins nod for hATTR amyloidosis
The US Food and Drug Administration has approved Alnylam’s RNAi therapeutic Onpattro for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.
Pharma lacks engagement with mental health groups: report
Janssen ranks first in new survey of pharma’s reputation among mental health patient groups
Medical & Scientific Advisors to get the recognition they deserve
PharmaTimes Media has announced the Medical & Scientific Excellence Awards as the latest addition to its highly prestigious portfolio of events.
